No Data
Don't Ignore The Insider Selling In Halozyme Therapeutics
We wouldn't blame Halozyme Therapeutics, Inc. (NASDAQ:HALO) shareholders if they were a little worried about the fact that Matthew Posard, the Independent Director recently netted about US$1.0m sellin
Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics(HALO.US) Director Sells US$1.01 Million in Common Stock
$Halozyme Therapeutics(HALO.US)$ Director Posard Matthew L. sold 20,000 shares of common stock on Jun 11, 12, 2024 at an average price of $50.315 for a total value of $1.01 million.Source: Announcemen
Halozyme Therapeutics Insider Sold Shares Worth $1,006,300, According to a Recent SEC Filing
Matthew L. Posard, Director, on June 11, 2024, sold 20,000 shares in Halozyme Therapeutics (HALO) for $1,006,300. Following the Form 4 filing with the SEC, Posard has control over a total of 99,755 sh
Form 144 | Halozyme Therapeutics(HALO.US) Director Proposes to Sell 1 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 11, $Halozyme Therapeutics(HALO.US)$ Director Posard Matthew L. intends to sell 20,000 shares of its common stock on Jun 11, with a total market value of approximately $1 m
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares soared 29.13% in the last week after reporting that its transf